Association of NOS3, VEGF, ACE and ACE2 polymorphisms with erectile dysfunction severity and tadalafil response in diabetic men

For millions of men, the ability to achieve and maintain an erection is a matter of simple biology, yet for those living with diabetes, this process often becomes complicated. The body relies on a delicate chemical chain reaction to trigger an erection. When a man is stimulated, a specific enzyme in the blood vessels of the penis releases a gas called nitric oxide. This gas acts as a signal, telling the smooth muscles in the penis to relax and allowing blood to flow in. In a healthy system, this happens smoothly. However, high blood sugar levels common in diabetes can damage the blood vessels and reduce the amount of nitric oxide available, breaking the chain before it even starts. To fix this, doctors often prescribe medications like tadalafil, which help the body hold onto the signal longer, making it easier for blood to stay in the penis. But these drugs do not work for everyone, and scientists have long wondered if a person's unique genetic code might explain why some men respond well while others see little change.

A team of researchers at the University Medical Centre Ljubljana set out to investigate this question specifically in men with diabetes. They focused on four genes that are known to play a role in blood vessel health and the chemical signals needed for an erection. These genes act like instruction manuals for building the proteins that control blood flow and tissue repair. The researchers wanted to know if small, natural variations in these instruction manuals could predict how severe a man's erectile difficulties would be, or whether they could forecast how well a man would respond to a daily dose of tadalafil. To find the answer, they enrolled seventy-eight men who had both diabetes and erectile dysfunction. Over the course of three months, every participant took a 5-milligram tablet of tadalafil once a day. Before starting the treatment and again after the three months were up, the men completed a standard questionnaire that measured their erectile function on a scale from zero to twenty-five.

The treatment itself worked well for the group as a whole. The average score on the questionnaire jumped significantly, moving from a baseline of fourteen to nearly twenty after three months. More than sixty percent of the men improved enough to be considered successful responders, meaning their scores increased by at least four points. This confirmed that the medication was effective for the majority of these patients. The researchers then turned their attention to the genetic data. They extracted DNA from blood samples and looked for specific variations in the four genes of interest. They compared the genetic makeup of the men who had the most severe problems at the start with those who had milder issues. They also compared the genes of the men who responded well to the drug against those who did not.

The results were clear and somewhat surprising. Despite the strong biological link between these genes and blood vessel function, the researchers found no evidence that the specific variations they tested could predict who would struggle with the condition or who would benefit most from the medication. Whether a man carried a certain version of the gene for nitric oxide production, vascular growth, or the enzymes that regulate blood pressure made no statistical difference in his outcome. There was one small, tentative signal found in a gene located on the X chromosome, which men carry only once. Men with a specific variation in this gene appeared to have lower odds of having moderate to severe erectile dysfunction before treatment began. However, when the researchers applied a strict mathematical correction to account for the number of different tests they ran, this single finding lost its statistical significance. It remains a hint rather than a rule.

Ultimately, this study suggests that for men with diabetes, the success of erectile dysfunction treatment cannot be easily predicted by looking at these common genetic markers. The complex damage caused by diabetes likely overwhelms the subtle effects of individual gene variations, making the condition too complicated to be solved by a single genetic test. While the medication helped most men, the researchers could not identify a genetic reason why some improved more than others. The findings point toward a future where understanding the full picture of diabetic erectile dysfunction will require looking at many factors at once, rather than searching for a single genetic key. For now, the best approach remains treating each patient individually, as the genetic variations in these specific genes do not appear to be the deciding factor in how well the treatment works.